News - Eli Lilly, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA

04-03-2014

Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Transition in new licensing deal with Eli Lilly

24-07-2013

Canada's Transition Therapeutics (TSX: TTH) has entered an exclusive licensing of worldwide rights to…

Anti-Arthritics/RheumaticsEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-601

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?

10-06-2013

Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

Thought leader views on new osteoporosis and osteopenia treatments

05-04-2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz

26-03-2013

Drug regulator Health Canada has approved German drug major Bayer's Stivarga (regorafenib tablets), indicated…

Anti-Arthritics/RheumaticsAsia-PacificBayerBiotechnologyBoehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaOncologyPfizerPharmaceuticalRegulationStivargaXeljanz

Lack of efficacy causes Eli Lilly to drop Ph III RA program for tabalumab

08-02-2013

US drug major Eli Lilly (NYSE: LLY) says that it will discontinue the Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Eli Lilly drops one tabalumab trial for RA

14-12-2012

US drug major Eli Lilly (NYSE: LLY) says that it will stop one of three Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Eli Lilly and Chugai to stop co-marketing of Evista in Japan

05-11-2012

The Japanese subsidiary of US drug major Eli Lilly (NYSE: LLY) and Roche's (ROG: SIX) majority-owned…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalEli LillyEvistaLicensingMarkets & MarketingPharmaceutical

ASBMR 2012: Anabolics and post-marketing studies

25-10-2012

This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

EMA advisory backs Humira for UC and expanded use of Byetta

20-02-2012

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on Friday…

Abbott LaboratoriesAmylinAnti-Arthritics/RheumaticsBiotechnologyByettaDiabetesEli LillyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

URMC research shows Lilly’s Forteo could extend life of arthritic joints

22-09-2011

A drug already approved to build bone mass in patients with osteoporosis also builds cartilage around…

Anti-Arthritics/RheumaticsEli LillyForteoPharmaceuticalResearch

Back to top